Abstract:Background/Objectives: Primary biliary cholangitis (PBC) is an autoimmune chronic cholestatic disease of the liver that symptomatically can present with pruritus and fatigue. Its established first- and second-line therapies are ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) although they provide limited symptom management. Liver transplantation offers a potentially curative therapeutic option in refractory cases progressing to cirrhosis. Novel research published after the current guidelines highlights the importance of providing an up-to-date analysis of treatment options available. Methods: In this study, we conducted a literature search using Pubmed, Ovid Medline, and SCOPUS to provide a narrative review of first-line, second-line, and emerging therapies in PBC. Results: UDCA has been well established as a long-term, safe therapy within the literature although it is possible that treatment dosage can be further optimised in refractory patients. It has a favourable side effect profile. Despite improving biochemical markers, histopathological profile, and overall outcomes, up to 30–40% of patients are refractory to it. Age and sex are highlighted as independent indicators of non-responsiveness. This necessitates effective second-line therapies. Future trials could aim to investigate UDCA as a co-first-line therapy. Further supporting results for OCA were found in the interim extension trial of the seminal POISE study. The long-term phase 4 COBOLT trial is still awaiting results to further assess the complications, adherence, and potential adverse effects. It is a viable option in UDCA-refractory patients. The high incidence rate of dose-related pruritis indicates that alternative second-line options are needed. Bezafibrate is an off-label antilipemic agent that shows promise as a prospective second-line therapy option. The landmark BEZURSO trial alleviated some efficacy and safety concerns, but it remains associated with elevated serum creatinine; thus, it should be considered with caution. Other prospective second-line therapies are budesonide, triple therapy, and novel agents such as seladelpar and elafibranor. Conclusions: UDCA should remain the treatment of choice for PBC, though perhaps not as monotherapy. With further investigation, BF shows promise as a new second-line therapy alongside OCA, which it may outperform.

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis— Time to change our targets?

Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon

Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

[Primary biliary cholangitis-response criteria of first-line treatment and perspectives of second-line therapy]

Response to Ursodeoxycholic Acid May Be Assessed Earlier to Allow Second-Line Therapy in Patients with Unresponsive Primary Biliary Cholangitis

Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis

Corrigendum To: "an International Genome-Wide Meta-Analysis of Primary Biliary Cholangitis: Novel Risk Loci and Candidate Drugs" [J Hepatol 75 (2021) 572-581].

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply

Corrigendum to 'an International Genome-Wide Meta-Analysis of Primary Biliary Cholangitis: Novel Risk Loci and Candidate Drugs' [J Hepatol 2021;75(3):572-581].

Primary biliary cholangitis: pathogenesis and therapeutic opportunities

New Treatment Paradigms in Primary Biliary Cholangitis

Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid

Advancing Second-Line Treatment for Primary Biliary Cholangitis

Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics

Novel therapeutic targets in primary biliary cirrhosis

Review of Current and Upcoming Second-Line Treatments for Primary Biliary Cholangitis

Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy